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 ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor Sir Michael Rawlins 
Secretary: Will Reynolds 
 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
Tel: 020 7035 0454  
Email: ACMD@homeoffice.gsi.gov.uk
 
 
Rt Hon Jacqui Smith MP 
Home Office 
2 Marsham Street  
London 
SW1P 4DF 
 
10th September 2008 
 
 
Dear Home Secretary,  
 
On 8th March 2008 the European Council responded to concerns over the 
misuse of the stimulant 1-benzylpiperazine (BZP) by subjecting it to ‘control 
measures and criminal provisions’ across the EU Member States. The 
Advisory Council on the Misuse of Drugs (ACMD) has considered the misuse 
of BZP and related compounds and I am pleased to enclose the ACMD’s 
report and advice. 
 
The ACMD recommends that BZP is brought under control of the Misuse of 
Drugs Act 1971. In addition, the ACMD recognises a group of substituted 
piperazines (of which BZP is one) which are, or have the potential to be, 
misused. The ACMD therefore recommends that these substances should be 
brought under the control of the Misuse of Drugs Act 1971 by means of a 
generic definition.  
 
Data from seizures by the forensic science providers indicate that several of 
the substituted 1-phenyl and 1-benzyl piperazines are also being misused; 
some appear to mimic or potentiate the effects of MDMA (‘ecstasy’). A generic 
definition would legislate for compounds that may otherwise need to be 
controlled separately, and would bring the UK into line with other countries 
that already control a number of substituted piperazines.  
 
The ACMD recognises the potential legitimate use of substances that would 
be covered by this generic definition and has identified options to mitigate 
against the impact of control for legitimate use.  
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The ACMD considers that the harms and misuse of BZP and substituted 
piperazines (identified in Annex 4) are commensurate with Class C, under 
schedule 2, part III, of the Misuse of Drugs Act (1971); and should be 
scheduled under Schedule I of the Misuse of Drugs Regulations (2001) 
(having no recognised medicinal use).  
 
 
Yours sincerely, 
 
 
Professor Sir Michael Rawlins FMedSci 
Chairman 
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 ACMD recommendation 
 
The ACMD recommends that 1-benzylpiperazine (BZP) is brought under 
control of the Misuse of Drugs Act 1971. In addition, the ACMD recognises a 
group of substituted piperazines identified in Annex 4 (of which BZP is one) 
which are, or have the potential to be, misused. The ACMD therefore 
recommends that these substances should be brought under the control of 
the Misuse of Drugs Act 1971 by means of a generic definition (see paragraph 
7.7).  
 
The ACMD considers that the harms and misuse of BZP and substituted 
piperazines (identified in Annex 4) are commensurate with Class C, under 
Schedule 2, part III, of the Misuse of Drugs Act (1971); and should be 
scheduled under Schedule I of the Misuse of Drugs Regulations (2001) 
(having no recognised medicinal use).  
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 1. Background 
 
1.1 The Advisory Council on the Misuse of Drugs (ACMD) is established 
under the Misuse of Drugs Act (1971). The ACMD’s terms of reference 
and current membership are shown in Annexes 1 and 2, respectively.   
 
1.2 The stimulant drug 1-benzylpiperazine (BZP) was initially brought to 
the ACMD Technical Committee’s attention in April 2006 when the 
Committee considered its chemistry and pharmacology.  
 
1.3 In 2007, the European Council proposed to make BZP subject to 
control measures across EU member states. The decision was based 
on the results of a risk-assessment report on BZP prepared by Europol 
and the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). This report, submitted to the European Council on 31st 
May 2007, considered the health and social risks of the drug alongside 
data on international trafficking and connections to organised crime.   
 
1.4 On the 23rd August 2007, the ACMD wrote to the Home Office, at its 
request, to provide advice for informing the UK’s position on BZP at EU 
negotiations (Annex 3). After reviewing the EMCDDA risk assessment, 
the ACMD supported the Commission’s proposal to make BZP subject 
to control measures under UK law.  
 
1.5 On 8th March 2008, the European Council responded to concerns over 
the illicit misuse of BZP by subjecting it to ‘control measures and 
criminal provisions’ across the EU Member States. Under the terms of 
the 2005 Council Decision1, Member States of the European Union 
have one year in which to implement appropriate controls on BZP 
under their domestic legislation and in accordance with the provisions 
of the 1971 United Nations Convention on Psychotropic Substances. 
 
The European Council decision states that: “due to its stimulant 
properties, risk to health, the lack of medical benefits and following the 
precautionary principle, there is a need to control BZP’, through 
measures ‘appropriate to the relatively low risks of the substance”.  
1.6 The EMCDDA press release of 3rd March 2008 concluded that BZP 
had no established or acknowledged medical value and there was no 
known licensed medicinal products containing the substance in the EU.  
 
1.7 On 20 March 2007, the Medicines and Healthcare products Regulatory 
Agency (MHRA) issued a notice that sale of products containing BZP 
was illegal and that vendors and producers could face prosecution 
(under the Medicines Act 1968)2. Since that time, the MHRA has 
                                                 
1 Council Decision 2005/387/JHA on information exchange, risk assessment and control of 
new psychoactive substances 
 
2 ‘Benzylpiperazine (PEP) pills are dangerous and illegal’, MHRA Press Release, 20 March 
2007 
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 investigated over 30 suppliers in the UK, some of which are being 
prosecuted, while others have been issued with formal cautions or 
advice. 
 
1.8 The ACMD was asked, by the Home Office, to undertake an 
assessment of BZP to consider classification and scheduling under the 
Misuse of Drugs Act (1971) and the Misuse of Drugs Regulations 
(2001). Neither BZP nor any related substituted piperazine are 
currently classified under the Misuse of Drugs Act (1971).  
 
1.9 This report presents the ACMD’s consideration of BZP and related 
compounds.  
 
 
2. Introduction 
 
2.1 BZP is a recreational stimulant, which gained popularity in some 
countries in the early 2000’s as a legal alternative to amphetamine, 
methylamphetamine, and 3, 4-methylenedioxy-N-methylamphetamine 
(MDMA - ecstasy). BZP is a central nervous system (CNS) stimulant 
with about 10% of the potency of d-amphetamine. 
 
2.2 Following reports of the misuse of BZP from a number of European 
countries, the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) carried out a risk assessment in mid-2007. The 
risk assessment report3, compiled by the scientific committee of 
EMCDDA, concluded that there was a need to control BZP. This 
conclusion was based on a more detailed review of BZP (the 
‘Technical Annexes’)4. The latter will be published by EMCDDA as part 
of the risk assessment monograph series5 in 2008.  
 
 
3. Pharmacology and harms to the individual 
 
3.1 BZP is a synthetic product. It is normally manufactured from 
piperazine, a substance that has been used for many years as an 
antihelminthic drug in the treatment of intestinal round worm 
infestations. Piperazine itself has no psychoactive properties. BZP was 
never developed as a potential antihelminthic drug, despite widespread 
statements to this effect in the scientific literature. Other myths 
                                                 
3 Risk Assessment Report of a new psychoactive substance: 1-benzylpiperazine (BZP) in 
accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk 
assessment and control of new psychoactive substances;  
https://ednd-cma.emcdda.europa.eu/assets/upload/Risk_Assessment_Report_BZP.pdf
4 L A King and S Elliott, Risk Assessment: 1-Benzylpiperazine (BZP): Draft Technical 
Annexes A-D (22 August 2007) 
5 http://www.emcdda.europa.eu/  
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 surrounding BZP include suggestions that it is of herbal origin and that 
it ‘contains’ piperazine.  
 
3.2 BZP was investigated by the Burroughs Wellcome Company as a 
potential antidepressant drug. This work was abandoned in the early 
1970’s when it was found that BZP was a central nervous system 
(CNS) stimulant with similar properties to amphetamine. 
 
3.3 A typical dose of BZP is about 100mg. Animal studies found that BZP 
can substitute for cocaine and amphetamine in self administration and 
discrimination studies6. There are limited human data on the misuse 
and dependence potential. The studies that exist, suggest a similarity 
to amphetamine. Clinical reports from patients who have consumed 
BZP suggest an association with grand mal seizures, even in those 
without any previous history of seizures. However, this finding is based 
on a very small number of cases. Users have reported a range of 
adverse reactions such as vomiting, headache, palpitations, poor 
appetite, stomach pains/nausea, anxiety, insomnia, strange thoughts, 
mood swings, confusion, irritability and tremors. Some of these 
occurred in the ‘comedown’ period, and some persisted for 24 hours 
after use6. 
 
3.4 BZP has been found in post mortem samples, however, the extent to 
which BZP was implicated in the deaths is not known; in all cases other 
drugs or other circumstances were involved.  
 
3.5 In October 2007, the Technical Committee conducted its own risk 
assessment of BZP based on a 9 point matrix7 (physical harms, 
dependence and societal harms). The assessment placed BZP at the 
lower end with other, less harmful, substances. 
 
 
4. Societal harms  
 
4.1 There is no direct evidence for any significant social harms (including 
acquisitive crime and anti social behaviour) being related to BZP use 
(see also 3.5 above).      
 
 
5. Use of BZP and other substituted piperazines  
 
5.1 BZP has no recognized legitimate medical or other commercial use; 
however, it can be used as a synthetic intermediate, for example for 
                                                 
6 Risk Assessment Report of a new psychoactive substance: 1-benzylpiperazine (BZP) in 
accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk 
assessment and control of new psychoactive substances;  
https://ednd-cma.emcdda.europa.eu/assets/upload/Risk_Assessment_Report_BZP.pdf
 
7 Nutt D, et al, 2007- Development of a rational scale to assess the harm of drugs of potential 
misuse. The Lancet. Volume 369: page 1047-1053 
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 the production of pharmaceuticals. The only substances listed in Annex 
4 that the ACMD have found to have legitimate uses are 1(3-
chlorophenyl) piperazine (mCPP) and 1-(3-chlorophenyl)-4-(3-
chloropropyl)-piperazine (CPCPP). The former is used as a probe of 
serotonin receptors in experimental neuropharmacology and as the 
precursor in the synthesis of several anti-depressant drugs (e.g. 
trazodone). CPCPP is a precursor used in the manufacture of the 
antidepressant drug nefazodone. Should mCPP and CPCPP become 
controlled drugs by virtue of a generic definition then two options exist: 
either issue a licence to those using them for scientific/industrial 
purposes or draft specific exclusions in the definition. The Association 
of the British Pharmaceutical Industry (ABPI) asked their members 
regarding use, but indicated that they did not have notification from any 
of their users of these compounds (mCPP or CPCPP).  
 
5.2 On 20 March 2007, the Medicines and Healthcare products Regulatory 
Agency (MHRA) issued a notice that sale of products containing BZP 
was illegal and that vendors and producers could face prosecution 
(under the Medicines Act 1968)8. The MHRA note that ‘BZP is not a 
licensed medicine in the UK and that it has no established 
therapeutic use. However, BZP fits the definition of a medicinal 
product set out in Article 1 of 2001/83/EC as it has marked 
pharmacological effects in humans and as such, requires a Marketing 
Authorisation (Product Licence) to be placed on the UK market9’.  
  
 
6. Seizures 
 
6.1 Illicitly-produced BZP usually occurs as either tablets or capsules, but 
loose powders are also found.  
 
6.2 Tablets and other illicit products containing BZP or other substituted 
piperazines first appeared in UK police drug seizures in early 2006. 
Since then the number of seizures has steadily increased. The 
Forensic Science Service currently examines around 400 cases in a 
quarterly period. The most commonly reported substances have been 
mCPP, BZP, 1,4-dibenzylpiperazine (DBZP) and 1-(3 
trifluoromethylphenyl)piperazine (TFMPP) often in various 
combinations and also in combination with other drugs such as 3,4-
methylenedioxy-N-methylamphetamine (MDMA – ‘ecstasy’) and 
amphetamine. During the period 2006-2007 there was a corresponding 
                                                 
8 ‘Benzylpiperazine (PEP) pills are dangerous and illegal’, MHRA Press Release, 20 March 
2007 
 
9 The sale, supply and advertisement of any unlicensed medicine contravenes the 
requirements of medicines legislation and consequently selling, supplying or offering for sale 
products containing BZP is unlawful.  
 Offences under the Medicines Act 1968 (and regulations made under it) are criminal and 
MHRA investigate identified illegal activity involving medicines and where appropriate, bring a 
prosecution through the criminal courts.’  
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 decrease in seizures containing only MDMA, suggesting that the 
‘piperazine group’ of drugs are being used as substitutes for MDMA. 
 
 
7. Options for control 
 
7.1 On April 1st 2008, the New Zealand Government placed BZP and five 
related substances (mCPP, TFMPP, pFPP, MeOPP and BZMP) into 
Class C of their Misuse of Drugs Act. In addition to the listed 
substances they also included the isomers of these substances - 
whenever the existence of such isomers is possible within the specific 
chemical designation. In four Member States – Belgium, Denmark, 
Greece and Malta – BZP is already subjected to control measures and 
criminal penalties as provided under their legislation by virtue of their 
obligations under the 1961 or 1971 UN Conventions10. In Sweden, 
Spain and the Netherlands BZP is controlled under other legislation. 
Eight countries in the EU control mCPP (Belgium, Cyprus, Denmark, 
Germany, Hungary, Lithuania, Malta and Slovakia), whilst control in 
Bulgaria is pending.  
 
7.3 BZP is one of several substituted piperazines, misuse of which has 
been reported in the UK and elsewhere in the EU in recent years. The 
misuse of one of these, 1(3-chlorophenyl) piperazine (mCPP), has 
been even more widespread than BZP11. The ACMD Technical 
Committee discussed a brief report12 on mCPP on 3rd November 2005. 
No risk assessment on mCPP was carried out at EU level because this 
substance was used to manufacture a number of active pharmaceutical 
ingredients (API) within the EU; it was therefore excluded from 
consideration under the terms of the 2005 Council Decision. However, 
mCPP has become the most widely encountered ‘new psychoactive 
substance’ since the EU monitoring process started in 1997. By 2006, 
it was estimated that almost 10% of illicit tablets sold in the EU, as part 
of the illicit ‘ecstasy’ market, contained mCPP10.  
 
7.4 The 11 most commonly-reported substituted piperazines can be 
divided into the 1-phenyl series and the 1-benzyl series; their structures 
are shown in Annex 4. Whereas BZP is a stimulant with properties 
similar to those of amphetamine, the others have a more complex 
pharmacology; some appear to mimic or potentiate the effects of 
MDMA (‘ecstasy’).   
                                                 
10 Risk Assessment Report of a new psychoactive substance: 1-benzylpiperazine (BZP) in 
accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk 
assessment and control of new psychoactive substances;  
https://ednd-cma.emcdda.europa.eu/assets/upload/Risk_Assessment_Report_BZP.pdf
11 Europol–EMCDDA Active Monitoring Report 
on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP) 
https://ednd-cma.emcdda.europa.eu/assets/upload/Final_Europol-
EMCDDA_Active_Monitoring_Report_mCPP_290307.pdf 
12 L A King, 1-(3-Chlorophenyl)piperazine (mCPP): A new psychoactive drug of abuse in 
Europe (25 October 2005). 
 
 10
  
7.5 The ACMD considered two options for UK control;  
 
Option one: BZP is controlled under Class C (in the same Class as 
GHB, Ketamine and tranquilizers), Schedule 2, of the Misuse of Drugs 
Act 1971 and under schedule I of the Misuse of Drugs Regulations.   
 
Option two: BZP and a group of substituted piperazines (identified in 
Annex 4) are controlled under Class C, Schedule 2, of the Misuse of 
Drugs Act 1971 and under Schedule I of the Misuse of Drugs 
Regulations.  
 
7.6 Although the UK is only required to implement controls on BZP, the 
ACMD recommend that a group of substituted piperazines should be 
brought under generic control (that would include BZP). Generic control 
would bring the UK into line with other countries that already control a 
number of substituted piperazines (paragraph 7.2) and would legislate 
for compounds that may otherwise have to be controlled separately 
e.g. mCPP, DBZP and TFMPP (see paragraph 7.3 for reported 
misuse).    
 
7.7 The proposed definition is: 
 
"1-benzylpiperazine and any compound structurally derived from 
1-benzylpiperazine or 1-phenylpiperazine by substitution in the 
aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, 
halide or haloalkyl substituents, whether or not substituted at the 
second nitrogen atom of the piperazine ring with alkyl, benzyl, 
haloalkyl, or phenyl substituents." 
 
7.8 Many examples exist within the Misuse of Drugs Act (1971) of generic 
definitions based on substitution patterns (phenethylamines, 
tryptamines, anabolic steroids etc.). Since their first introduction in 
1977, these definitions have been extremely successful; the ACMD are 
not aware of any forensic-chemical or other legal problems that have 
arisen and nor have the controls impeded drug development in the 
pharmaceutical industry13. In some of the generically-defined groups, 
the structural definitions subsume substances from more than one 
pharmacological group, as well as substances that may have no 
pharmacological activity at all.  
 
7.9 The above definition captures the substances listed in Annex 4. 
However, it is essential that the definition does not inadvertently 
subsume an API, a number of which are based on substituted 
piperazines. The most closely related group of API derived from 
piperazine include cyclizine (1-diphenylmethyl-4-methylpiperazine) and 
                                                 
13 L.A.King, The Misuse of Drugs Act: A Guide for Forensic Scientists,  Royal Society of 
Chemistry, London (2003) 
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 its many derivatives14. None of these, nor more distantly-related 
substances (e.g. diethylcarbamazine, vanoxerine and trazodone) fall 
within the definition (paragraph 7.7). A structure search of the Merck 
Index (12th Edition, 1996) revealed no other contentious structures. 
 
 
8. Conclusions and recommendations 
 
8.1 The European Council has subjected BZP to ‘control measures and 
criminal provisions’ across the EU Member States. The UK is therefore 
obliged to implement appropriate controls on BZP under the Misuse of 
Drugs Act 1971.   
 
8.2 The ACMD recommends that BZP is brought under control of the 
Misuse of Drugs Act 1971.  
 
8.3 Data from seizures by the forensic service providers indicate that 
several of the substituted 1-phenyl and 1-benzyl piperazines identified 
in this report (Annex 4) are being misused and some appear to mimic 
or potentiate the effects of MDMA (‘ecstasy’). The ACMD therefore 
recommends that these substances should be brought under the 
control of the Misuse of Drugs Act 1971 by means of a generic 
definition (that would include BZP - see paragraph 7.7).  
 
8.4 The ACMD considers that the harms and misuse of BZP and 
substituted piperazines (identified in Annex 4) are commensurate with 
Class C, under Schedule 2, part III, of the Misuse of Drugs Act (1971); 
and should be scheduled under Schedule I of the Misuse of Drugs 
Regulations (2001) (having no recognised medicinal use).  
 
 
                                                 
14 The cyclizine group includes, inter alia, meclizine, chlorcyclizine, flunarizine, lomerizine and 
cetrizine. 
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 Annex 1. ACMD Terms of Reference  
 
“ It shall be the duty of the Advisory Council to keep under review the situation 
in the United Kingdom with respect to drugs which are being or appear to 
them likely to be misused and of which the misuse is having or appears to 
them capable of having harmful effects sufficient to constitute a social 
problem, and to give to any one or more of the Ministers, where either Council 
consider it expedient to do so or they are consulted by the Minister or 
Ministers in question, advice on measures (whether or not involving alteration 
of the law) which in the opinion of the Council ought to be taken for preventing 
the misuse of such drugs or dealing with social problems connected with their 
misuse, and in particular on measures which in the opinion of the Council, 
ought to be taken:  
  
a)         for restricting the availability of such drugs or supervising the 
arrangements for their supply; 
 
b)         for enabling persons affected by the misuse of such drugs to obtain 
proper advice, and for securing the provision of proper facilities and services 
for the treatment, rehabilitation and after-care of such persons; 
  
c)         for promoting co-operation between the various professional and 
community services which in the opinion of the Council have a part to play in 
dealing with social problems connected with the misuse of drugs; 
  
d)         for educating the public (and in particular the young) in the dangers of 
misusing such drugs and for giving publicity to those dangers; and  
  
e)         for promoting research into, or otherwise obtaining information about, 
any matter which in the opinion of the Council is of relevance for the purpose 
of preventing the misuse of such drugs or dealing with any social problem 
connected with their misuse”.  
  
A further duty is placed on the Council by the Act to consider any matter 
relating to drug dependence or the misuse of drugs which may be referred to 
them by any one of the Ministers concerned, and in particular to consider and 
advise the Home Secretary on any communication which he refers to the 
Council which relates to the control of a dangerous or otherwise harmful drug 
and which is made to Her Majesty’s Government by any organisation or 
authority established by treaty, convention or other agreement or arrangement 
to which Her Majesty’s Government is a party. 
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 Annex 2. ACMD current membership 
 
Professor Sir Michael Rawlins  
 
Chair, National Institute for Health 
and Clinical Excellence 
Dr Dima Abdulrahim  
 
Briefings Manager, National 
Treatment Agency 
Lord Victor Adebowale  
 
Chief Executive, Turning Point 
Mr Martin Barnes  
 
Chief Executive, Drugscope 
Dr Margaret Birtwistle  
 
Specialist General Practitioner, 
Senior Tutor – Education and 
Training Unit, St George’s Hospital 
and Forensic Medical Examiner 
 
Commander Simon Bray  
 
Commander, Metropolitan Police 
Professor Simon Campbell Scientific Consultant  
 
Mr Eric Carlin  
 
Chief Executive, Mentor UK 
Ms Carmel Clancy  
 
Principal Lecturer in Mental Health 
and Addiction, 
Middlesex University 
Professor Ilana Crome  
 
Professor of Addiction Psychiatry, 
Keele University Medical School 
Ms Robyn Doran  
 
Mental health nurse and Director of 
Operations, North-West London 
Mental Health Trust 
Dr Clare Gerada  
 
General Practitioner, London, and 
Primary Care Lead for Drug Misuse, 
Royal College of General 
Practitioners 
Mr Patrick Hargreaves  
 
Adviser for drugs and alcohol, 
Durham County Council Education 
Department 
Ms Caroline Healy  
 
National adviser for the 
commissioning of mental health 
services for children in secure 
settings, Department of Health 
Dr Matthew Hickman  
 
Reader in Public Health and 
Epidemiology, 
Department of Social Medicine, 
University of Bristol 
Professor Leslie Iversen  
 
Professor of Pharmacology, Oxford 
University 
 
Dr Leslie King  
 
Former Head of Drugs Intelligence 
Unit, Forensic Science Service 
Professor Michael Lewis  Professor of Oral Medicine, Cardiff 
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  University 
Mr David Liddell  
 
Director, Scottish Drugs Forum 
Dr John Marsden  
 
 
Research Psychologist, Institute of 
Psychiatry 
 
Mr Peter Martin  
 
Independent consultant in substance 
misuse 
Professor David Nutt  
 
Director of Psychopharmacology Unit, 
Bristol University 
Mr Trevor Pearce  
 
Director of Enforcement, Serious 
Organised Crime Agency 
District Judge Justin Philips  
 
District Judge, drugs court 
Mr Richard Phillips  
 
Independent consultant in substance 
misuse 
Dr Ian Ragan  
 
Pharmaceutical industry consultant 
DCC Howard Roberts  
 
Deputy Chief Constable, 
Nottinghamshire Police 
Dr Mary Rowlands  
 
Consultant psychiatrist in substance 
misuse, Exeter 
Dr Polly Taylor  
 
Veterinary surgeon, Cambridgeshire 
Ms Monique Tomlinson  
 
Freelance consultant in drugs misuse 
Mrs Marion Walker  
 
Pharmacist, Berkshire Healthcare 
NHS Foundation Trust 
Mr Arthur Wing  Assistant Chief Officer, Sussex 
Probation Area 
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 Annex 3. ACMD letter to the Home Office (23rd August 2007) 
regarding BZP.  
 
ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor Sir Michael Rawlins 
Secretary: Will Reynolds 
 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
Tel: 020 7035 0454  
Email: ACMD@homeoffice.gsi.gov.uk
James Marmion, 
6th Floor, Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
 
23rd August 2007 
 
 
 
 
Dear James, 
 
The Advisory Council on the Misuse of Drugs’ Technical Committee 
discussed BZP in November 2006 and March 2007. Although the ACMD were 
not formally asked by the Home Office to consider the substance I am 
pleased to provide the following advice to assist in informing the UK’s position 
at the Horizontal Drugs Group on the 5th September 2007.  
 
The Technical Committee considered a number of publications relating to 
BZP from New Zealand where the misuse of BZP is problematic. The 
Technical Committee has not convened, as yet, a dedicated working group on 
this issue. Such a group may be convened after a decision, at European level, 
has been made.  
   
After reviewing the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) risk assessment the ACMD supports the Commission’s proposal 
to make BZP subject to control measures under UK Law. The Home Office 
should bear in mind that control measures should be appropriate to the 
relatively low risks of this substance, but overall the position is proportional 
and in line with the Technical Committee's thinking. 
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 If the decision to classify BZP is taken at European level then the ACMD will 
offer further advice on classification under the MDA 1971.  
  
If however, the decision is taken not to control BZP at the European level the 
ACMD will be willing to offer further advice relating to the UK position and 
harm reduction measures.    
 
The ACMD look forward to being updated on the Commission’s position in the 
near future 
 
Yours sincerely, 
 
 
 
Professor Sir Michael Rawlins 
Chairman 
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 Annex 4. Substituted piperazines (1-pheny and 1-benzyl) that 
would be subsumed under the proposed generic definition 
(paragraph 7.7).  
 
NNR1
R2
R3
 
 
The general structure of a substituted phenylpiperazine 
Table 1 Phenylpiperazines 
 
Name (acronym) R1 R2 R3
1-(3-Chlorophenyl)piperazine (mCPP) H Cl H 
1-(4-Chlorophenyl)piperazine (pCPP) Cl H H 
1-(4-Fluorophenyl)piperazine (pFPP) F H H 
1-(3-Trifluoromethylphenyl) piperazine (TFMPP) H CF3 H 
1-(3-Methylphenyl) piperazine (mMPP) H CH3 H 
1-(4-Methylphenyl) piperazine (pMPP) CH3 H H 
1-(4-Methoxyphenyl) piperazine (pMeOPP) CH3O H H 
1-(3-Chlorophenyl)-4-(3-chloropropyl)piperazine 
(CPCPP) 
H Cl CH2CH2-
CH2Cl 
 
 18
  
CH2
N
N
R4 
 
The general structure of a substituted benzylpiperazine 
 
Table 2 Benzylpiperazines 
Name (acronym) R4
1-Benzylpiperazine (BZP) H 
1,4-Dibenzylpiperazine (DBZP) C6H5-CH2
1-Benzyl-4-methylpiperazine (BZMP) CH3
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